AU2012332814B2 - Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain - Google Patents

Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain Download PDF

Info

Publication number
AU2012332814B2
AU2012332814B2 AU2012332814A AU2012332814A AU2012332814B2 AU 2012332814 B2 AU2012332814 B2 AU 2012332814B2 AU 2012332814 A AU2012332814 A AU 2012332814A AU 2012332814 A AU2012332814 A AU 2012332814A AU 2012332814 B2 AU2012332814 B2 AU 2012332814B2
Authority
AU
Australia
Prior art keywords
synuclein
antibody
level
brain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012332814A
Other languages
English (en)
Other versions
AU2012332814A1 (en
Inventor
Thomas ENGBER
Jan Grimm
Andreas Weihoffen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen International Neuroscience GmbH
Original Assignee
Biogen International Neuroscience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen International Neuroscience GmbH filed Critical Biogen International Neuroscience GmbH
Publication of AU2012332814A1 publication Critical patent/AU2012332814A1/en
Assigned to BIOGEN INTERNATIONAL NEUROSCIENCE GMBH reassignment BIOGEN INTERNATIONAL NEUROSCIENCE GMBH Amend patent request/document other than specification (104) Assignors: BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBH
Application granted granted Critical
Publication of AU2012332814B2 publication Critical patent/AU2012332814B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2012332814A 2011-11-02 2012-10-29 Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain Ceased AU2012332814B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161554924P 2011-11-02 2011-11-02
US61/554,924 2011-11-02
PCT/US2012/062430 WO2013066818A1 (en) 2011-11-02 2012-10-29 USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN

Publications (2)

Publication Number Publication Date
AU2012332814A1 AU2012332814A1 (en) 2014-06-12
AU2012332814B2 true AU2012332814B2 (en) 2017-12-14

Family

ID=48192661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012332814A Ceased AU2012332814B2 (en) 2011-11-02 2012-10-29 Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain

Country Status (13)

Country Link
US (3) US20140295465A1 (enExample)
EP (1) EP2773957B1 (enExample)
JP (1) JP6263473B2 (enExample)
KR (1) KR102036938B1 (enExample)
CN (2) CN107091931A (enExample)
AU (1) AU2012332814B2 (enExample)
BR (1) BR112014010664A2 (enExample)
CA (1) CA2854131C (enExample)
EA (1) EA034213B1 (enExample)
IL (1) IL232373B (enExample)
MX (1) MX356797B (enExample)
WO (1) WO2013066818A1 (enExample)
ZA (1) ZA201403879B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
LT2723379T (lt) 2011-06-23 2018-10-25 Biogen International Neuroscience Gmbh Anti-alfa sinukleiną rišančios molekulės
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
JP6273338B1 (ja) * 2016-12-05 2018-01-31 磁量生技股▲ふん▼有限公司 パーキンソン病からパーキンソン病認知症を特定する方法
WO2018128454A1 (ko) * 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
CN116731173A (zh) 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
EP3629021A1 (en) * 2018-09-26 2020-04-01 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
US20110052498A1 (en) * 2008-04-29 2011-03-03 Lars Lannfelt Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
WO1999050300A1 (en) * 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
CN1440420A (zh) * 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α－共核蛋白疾病的方法
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
US8906367B2 (en) 2007-01-05 2014-12-09 University Of Zurich Method of providing disease-specific binding molecules and targets
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
US20110052498A1 (en) * 2008-04-29 2011-03-03 Lars Lannfelt Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies

Also Published As

Publication number Publication date
MX2014005378A (es) 2015-01-19
AU2012332814A1 (en) 2014-06-12
US20180011112A1 (en) 2018-01-11
EP2773957B1 (en) 2017-11-29
CA2854131A1 (en) 2013-05-10
US20190094245A1 (en) 2019-03-28
CA2854131C (en) 2020-07-07
ZA201403879B (en) 2018-11-28
EP2773957A1 (en) 2014-09-10
BR112014010664A2 (pt) 2017-04-25
CN107091931A (zh) 2017-08-25
EA201490883A1 (ru) 2014-10-30
KR102036938B1 (ko) 2019-10-25
HK1201585A1 (en) 2015-09-04
CN104040342A (zh) 2014-09-10
IL232373B (en) 2018-08-30
EA034213B1 (ru) 2020-01-17
JP2014533357A (ja) 2014-12-11
WO2013066818A1 (en) 2013-05-10
US20140295465A1 (en) 2014-10-02
JP6263473B2 (ja) 2018-01-31
MX356797B (es) 2018-06-14
EP2773957A4 (en) 2015-06-24
KR20140095074A (ko) 2014-07-31
NZ625217A (en) 2016-07-29
IL232373A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
AU2012332814B2 (en) Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain
JP7227312B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
US9849165B2 (en) Oligomer-specific amyloid beta epitope and antibodies
ES2773961T3 (es) Uso de moléculas de unión a semaforina-4D para el tratamiento de trastornos neurodegenerativos
JP2019108359A (ja) アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用
JP7626416B2 (ja) 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
CA2894178A1 (en) A method of reducing brain amyloid plaques using anti-a.beta. antibodies
TW201542589A (zh) 偵測人類ｐｅｒｉｏｓｔｉｎ之新穎分析法
HK1201585B (en) Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain
NZ625217B2 (en) Use of an anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain
AU2013205000B2 (en) Oligomer-specific amyloid beta epitope and antibodies
HK1231887A1 (en) Oligomer-specific amyloid beta epitope and antibodies
HK1185350B (en) Oligomer-specific amyloid beta epitope and antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired